☰

Everett M. Stone, Ph.D. - Publications

Affiliations: 
2006 ICMB University of Texas at Austin, Austin, Texas, U.S.A. 
Area:
Biochemistry, Molecular Biology
Tree Info Similar researchers PubMed Report error

53 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Blazeck J, Karamitros CS, Ford K, Somody C, Qerqez A, Murray K, Burkholder NT, Marshall N, Sivakumar A, Lu WC, Tan B, Lamb C, Tanno Y, Siddiqui MY, Ashoura N, ... ... Stone E, et al. Bypassing evolutionary dead ends and switching the rate-limiting step of a human immunotherapeutic enzyme. Nature Catalysis. 5: 952-967. PMID 36465553 DOI: 10.1038/s41929-022-00856-6  0.375
2022 Karamitros CS, Murray K, Winemiller B, Lamb C, Stone EM, D'Arcy S, Johnson KA, Georgiou G. Leveraging intrinsic flexibility to engineer enhanced enzyme catalytic activity. Proceedings of the National Academy of Sciences of the United States of America. 119: e2118979119. PMID 35658075 DOI: 10.1073/pnas.2118979119  0.387
2020 Karamitros CS, Murray K, Sugiyama Y, Kumada Y, Johnson KA, Georgiou G, D'Arcy S, Stone EM. Conformational Dynamics Contribute to Substrate Selectivity and Catalysis in Human Kynureninase. Acs Chemical Biology. PMID 33275413 DOI: 10.1021/acschembio.0c00676  0.345
2020 Lu WC, Saha A, Yan W, Garrison K, Lamb C, Pandey R, Irani S, Lodi A, Lu X, Tiziani S, Zhang YJ, Georgiou G, DiGiovanni J, Stone E. Enzyme-mediated depletion of serum l-Met abrogates prostate cancer growth via multiple mechanisms without evidence of systemic toxicity. Proceedings of the National Academy of Sciences of the United States of America. PMID 32434918 DOI: 10.1073/Pnas.1917362117  0.423
2020 Badgley MA, Kremer DM, Maurer HC, DelGiorno KE, Lee HJ, Purohit V, Sagalovskiy IR, Ma A, Kapilian J, Firl CEM, Decker AR, Sastra SA, Palermo CF, Andrade LR, Sajjakulnukit P, ... ... Stone E, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science (New York, N.Y.). 368: 85-89. PMID 32241947 DOI: 10.1126/Science.Aaw9872  0.346
2019 Cao JY, Poddar A, Magtanong L, Lumb JH, Mileur TR, Reid MA, Dovey CM, Wang J, Locasale JW, Stone E, Cole SPC, Carette JE, Dixon SJ. A Genome-wide Haploid Genetic Screen Identifies Regulators of Glutathione Abundance and Ferroptosis Sensitivity. Cell Reports. 26: 1544-1556.e8. PMID 30726737 DOI: 10.1016/J.Celrep.2019.01.043  0.312
2019 Coma S, Cavanaugh J, Nolan J, Tchaicha J, McGovern K, Stone E, Blazeck J, Lamb C, Georgiou G, Manfredi MG, Zhang M. Abstract B008: Treatment of IDO1 and TDO2 positive tumors with a kynurenine-degrading enzyme: A highly differentiated approach from IDO1 inhibition Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-B008  0.414
2019 Wilder CS, Saha A, Georgiou G, Stone E, DiGiovanni J. Abstract 2996: Systemic depletion of L-methionine with an engineered human enzyme for the treatment of melanoma Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2996  0.382
2019 Gjuka D, Georgiou G, Stone EM. Abstract LB-A18: The frequent tumor deletion of MTAP is a newly recognized potent immune checkpoint that is effectively reversed by a human methylthioadenosine degrading drug candidate Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-Lb-A18  0.368
2018 Triplett TA, Garrison KC, Marshall N, Donkor M, Blazeck J, Lamb C, Qerqez A, Dekker JD, Tanno Y, Lu WC, Karamitros CS, Ford K, Tan B, Zhang XM, McGovern K, ... ... Stone E, et al. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nature Biotechnology. PMID 30010674 DOI: 10.1038/Nbt.4180  0.4
2018 Kshattry S, Georgiou G, Tiziani S, Saha A, Stone E, DiGiovanni J. Abstract 3963: Cystine depleting human enzyme combined with auranofin synergistically inhibits pancreatic cancer cell growth in vitro and in vivo Cancer Research. 78: 3963-3963. DOI: 10.1158/1538-7445.Am2018-3963  0.374
2018 Coma S, Cavanaugh J, Nolan J, Tchaicha J, McGovern K, Stone E, Lamb C, Karamitros C, Blazek J, Garrison K, Georgiou G, Manfredi M, Zhang XM. Abstract 3757: Targeting the IDO/TDO pathway through degradation of the immunosuppressive metabolite kynurenine Cancer Research. 78: 3757-3757. DOI: 10.1158/1538-7445.Am2018-3757  0.402
2017 Poursaitidis I, Wang X, Crighton T, Labuschagne C, Mason D, Cramer SL, Triplett K, Roy R, Pardo OE, Seckl MJ, Rowlinson SW, Stone E, Lamb RF. Oncogene-Selective Sensitivity to Synchronous Cell Death following Modulation of the Amino Acid Nutrient Cystine. Cell Reports. 18: 2547-2556. PMID 28297659 DOI: 10.1016/J.Celrep.2017.02.054  0.35
2017 Yan W, Stone EM, Zhang YJ. Structural snapshots of an engineered cystathionine-Υ-lyase reveal the critical role of electrostatic interactions in the active-site. Biochemistry. PMID 28106980 DOI: 10.1021/Acs.Biochem.6B01172  0.469
2017 Triplett TA, Triplett K, Stone E, Zhang M, Manfredi M, Lamb C, Tanno Y, Ehrlich L, Georgiou G. Abstract 5571: Immune-checkpoint inhibition via enzyme-mediated degradation of kynurenine Cancer Research. 77: 5571-5571. DOI: 10.1158/1538-7445.Am2017-5571  0.391
2017 Zhang M, Stone E, Triplett TA, Triplett K, Lamb C, Karamitros CS, Blazek J, Georgiou G, Manfredi MG. Abstract 5570: A novel approach to targeting the IDO/TDO pathway through degradation of the immunosuppressive metabolite kynurenine Cancer Research. 77: 5570-5570. DOI: 10.1158/1538-7445.Am2017-5570  0.405
2017 Saha A, Cramer SL, Kshattry S, Tiziani S, Stone E, Georgiou G, DiGiovanni J. Abstract 2132: Novel therapeutic approach through systemic depletion of L-cyst(e)ine with engineered cyst(e)inase enzyme for suppression of prostate tumor growth Cancer Research. 77: 2132-2132. DOI: 10.1158/1538-7445.Am2017-2132  0.415
2017 Kshattry S, Saha A, Cramer S, DiGiovanni J, Tiziani S, Munoz N, Georgiou G, Stone E. Abstract 105: Depletion of extracellular cystine and cysteine by a mutagenized human enzyme causes ROS mediated cytotoxicity in pancreatic cancer cells Cancer Research. 77: 105-105. DOI: 10.1158/1538-7445.Am2017-105  0.415
2016 Cramer SL, Saha A, Liu J, Tadi S, Tiziani S, Yan W, Triplett K, Lamb C, Alters SE, Rowlinson S, Zhang YJ, Keating MJ, Huang P, DiGiovanni J, Georgiou G, ... Stone E, et al. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth. Nature Medicine. PMID 27869804 DOI: 10.1038/Nm.4232  0.407
2016 Li W, Irani S, Crutchfield A, Hodge K, Matthews W, Patel P, Zhang YJ, Stone EM. Intramolecular cleavage of the hASRGL1 homodimer occurs in two stages. Biochemistry. PMID 26780688 DOI: 10.1021/Acs.Biochem.5B01157  0.383
2016 Agnello G, Alters S, Tyler J, Liu J, Huang P, Stone E, Georgiou G, Lowe D, Rowlinson S. Development of a Human Therapeutic L-Cyst(e)Ine-Degrading Enzyme for the Treatment of Hematological Malignancies Blood. 128: 1587-1587. DOI: 10.1182/Blood.V128.22.1587.1587  0.388
2016 Kshattry S, Saha A, Cramer S, Stone EM, Georgiou G, JD. Abstract 367: Assessing the therapeutic efficacy of Cyst(e)inase to induce oxidative stress mediated cytotoxicity in pancreatic cancer cells Cancer Research. 76: 367-367. DOI: 10.1158/1538-7445.Am2016-367  0.357
2016 Liu J, Feng L, Stone EM, Tyler J, Rowlinson SW, Keating MJ, Huang P. Abstract 3073: Targeting chronic lymphocytic leukemia by interfering glutathione synthesis using a novel therapeutic enzyme cyst(e)inase (AEB3103) Cancer Research. 76: 3073-3073. DOI: 10.1158/1538-7445.Am2016-3073  0.359
2016 Rowlinson SW, Alters SE, Agnello G, Tyler J, Lowe A, Okamoto-Kearney M, Johnson D, Stone E, Georgiou G, Lowe DG. Abstract 1042: Development of AEB1102, an engineered human arginase 1 for patients with solid tumors Cancer Research. 76: 1042-1042. DOI: 10.1158/1538-7445.Am2016-1042  0.401
2015 Burrage LC, Sun Q, Elsea SH, Jiang MM, Nagamani SC, Frankel AE, Stone E, Alters SE, Johnson DE, Rowlinson SW, Georgiou G, Lee BH. Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency. Human Molecular Genetics. PMID 26358771 DOI: 10.1093/Hmg/Ddv352  0.361
2015 Khoury O, Ghazale N, Stone E, El-Sibai M, Frankel AE, Abi-Habib RJ. Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells. Journal of Neuro-Oncology. 122: 75-85. PMID 25567351 DOI: 10.1016/S0959-8049(14)50671-5  0.354
2015 Chrysostomou C, Quandt EM, Marshall NM, Stone E, Georgiou G. An alternate pathway of arsenate resistance in E. coli mediated by the glutathione S-transferase GstB. Acs Chemical Biology. 10: 875-82. PMID 25517993 DOI: 10.1021/Cb500755J  0.376
2015 Stone E, Marshall N, Donkor M, Triplett K, Blazek J, Triplett T, Ehrlich L, Georgiou G. Abstract LB-226: Depletion of kynurenine using an engineered therapeutic enzyme potently inhibits cancer immune checkpoints both as a monotherapy and in combination with anti-PD-1 Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-226  0.355
2014 Agrawal V, Woo JH, Mauldin JP, Stone EM, Meininger CJ, Jo C, Kleypas K, Frenkel EP, Frankel AE. In-vivo evaluation of human recombinant Co-arginase against A375 melanoma xenografts. Melanoma Research. 24: 556-67. PMID 25304236 DOI: 10.1097/Cmr.0000000000000119  0.376
2013 Tanios R, Bekdash A, Kassab E, Stone E, Georgiou G, Frankel AE, Abi-Habib RJ. Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells. Leukemia Research. 37: 1565-71. PMID 24018014 DOI: 10.1016/J.Leukres.2013.08.007  0.332
2013 Agnello G, Chang LL, Lamb CM, Georgiou G, Stone EM. Discovery of a substrate selectivity motif in amino acid decarboxylases unveils a taurine biosynthesis pathway in prokaryotes. Acs Chemical Biology. 8: 2264-71. PMID 23972067 DOI: 10.1021/Cb400335K  0.423
2013 Paley O, Agnello G, Cantor J, Yoo TH, Georgiou G, Stone E. GFP reporter screens for the engineering of amino acid degrading enzymes from libraries expressed in bacteria. Methods in Molecular Biology (Clifton, N.J.). 978: 31-44. PMID 23423887 DOI: 10.1007/978-1-62703-293-3_3  0.417
2012 Stone E, Paley O, Hu J, Ekerdt B, Cheung NK, Georgiou G. De novo engineering of a human cystathionine-γ-lyase for systemic (L)-Methionine depletion cancer therapy. Acs Chemical Biology. 7: 1822-9. PMID 22963240 DOI: 10.1021/Cb300335J  0.432
2012 Li W, Cantor JR, Yogesha SD, Yang S, Chantranupong L, Liu JQ, Agnello G, Georgiou G, Stone EM, Zhang Y. Uncoupling intramolecular processing and substrate hydrolysis in the N-terminal nucleophile hydrolase hASRGL1 by circular permutation. Acs Chemical Biology. 7: 1840-7. PMID 22891768 DOI: 10.1021/Cb300232N  0.472
2012 Romero PA, Stone E, Lamb C, Chantranupong L, Krause A, Miklos AE, Hughes RA, Fechtel B, Ellington AD, Arnold FH, Georgiou G. SCHEMA-designed variants of human Arginase I and II reveal sequence elements important to stability and catalysis. Acs Synthetic Biology. 1: 221-8. PMID 22737599 DOI: 10.1021/Sb300014T  0.395
2012 Mauldin JP, Zeinali I, Kleypas K, Woo JH, Blackwood RS, Jo CH, Stone EM, Georgiou G, Frankel AE. Recombinant human arginase toxicity in mice is reduced by citrulline supplementation. Translational Oncology. 5: 26-31. PMID 22348173 DOI: 10.1593/Tlo.11262  0.349
2012 Cantor JR, Panayiotou V, Agnello G, Georgiou G, Stone EM. Engineering reduced-immunogenicity enzymes for amino acid depletion therapy in cancer. Methods in Enzymology. 502: 291-319. PMID 22208990 DOI: 10.1016/B978-0-12-416039-2.00015-X  0.456
2012 Stone E, Chantranupong L, Gonzalez C, O'Neal J, Rani M, VanDenBerg C, Georgiou G. Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy. Journal of Controlled Release : Official Journal of the Controlled Release Society. 158: 171-9. PMID 22001609 DOI: 10.1016/J.Jconrel.2011.09.097  0.393
2012 Agrawal V, Woo JH, Mauldin JP, Jo C, Stone EM, Georgiou G, Frankel AE. Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells. Anti-Cancer Drugs. 23: 51-64. PMID 21955999 DOI: 10.1097/Cad.0B013E32834Ae42B  0.352
2011 Glazer ES, Stone EM, Zhu C, Massey KL, Hamir AN, Curley SA. Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. Translational Oncology. 4: 138-46. PMID 21633669 DOI: 10.1593/Tlo.10265  0.39
2011 Cantor JR, Stone EM, Georgiou G. Expression and biochemical characterization of the human enzyme N-terminal asparagine amidohydrolase. Biochemistry. 50: 3025-33. PMID 21375249 DOI: 10.1021/Bi101832W  0.4
2010 Stone EM, Chantranupong L, Georgiou G. The second-shell metal ligands of human arginase affect coordination of the nucleophile and substrate. Biochemistry. 49: 10582-8. PMID 21053939 DOI: 10.1021/Bi101542T  0.412
2010 Stone EM, Glazer ES, Chantranupong L, Cherukuri P, Breece RM, Tierney DL, Curley SA, Iverson BL, Georgiou G. Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines. Acs Chemical Biology. 5: 333-42. PMID 20050660 DOI: 10.1021/Cb900267J  0.406
2010 Stone EM, Glazer ES, Chantranupong L, Cherukuri P, Breece RM, Tierney DL, Curley SA, Iverson BL, Georgiou G. Erratum: Replacing Mn2+ with Co2+ in human arginase I enhances cytotoxicity toward L-arginine auxotrophic cancer cell lines (ACS Chemical Biology (2010) 5 (333-342) Acs Chemical Biology. 5. DOI: 10.1021/Cb1001813  0.326
2010 Glazer E, Stone E, Kaluarachchi W, Chantranupong L, Massey K, Georgiou G, Curley S. Bioengineered Human L-Arginase Is Cytotoxic to Hepatocellular and Pancreatic Carcinoma Cells through Induction of Proapoptotic Pathways Journal of Surgical Research. 158: 338-339. DOI: 10.1016/J.Jss.2009.11.460  0.314
2009 Cantor JR, Stone EM, Chantranupong L, Georgiou G. The human asparaginase-like protein 1 hASRGL1 is an Ntn hydrolase with beta-aspartyl peptidase activity. Biochemistry. 48: 11026-31. PMID 19839645 DOI: 10.1021/Bi901397H  0.369
2008 Linsky TW, Monzingo AF, Stone EM, Robertus JD, Fast W. Promiscuous partitioning of a covalent intermediate common in the pentein superfamily. Chemistry & Biology. 15: 467-75. PMID 18482699 DOI: 10.1016/J.Chembiol.2008.03.012  0.664
2006 Stone EM, Costello AL, Tierney DL, Fast W. Substrate-assisted cysteine deprotonation in the mechanism of dimethylargininase (DDAH) from Pseudomonas aeruginosa. Biochemistry. 45: 5618-30. PMID 16634643 DOI: 10.1021/Bi052595M  0.666
2005 Stone EM, Schaller TH, Bianchi H, Person MD, Fast W. Inactivation of two diverse enzymes in the amidinotransferase superfamily by 2-chloroacetamidine: dimethylargininase and peptidylarginine deiminase. Biochemistry. 44: 13744-52. PMID 16229464 DOI: 10.1021/Bi051341Y  0.685
2005 Liu D, Lepore BW, Petsko GA, Thomas PW, Stone EM, Fast W, Ringe D. Three-dimensional structure of the quorum-quenching N-acyl homoserine lactone hydrolase from Bacillus thuringiensis. Proceedings of the National Academy of Sciences of the United States of America. 102: 11882-7. PMID 16087890 DOI: 10.1073/Pnas.0505255102  0.644
2005 Stone EM, Fast W. A continuous spectrophotometric assay for dimethylarginine dimethylaminohydrolase. Analytical Biochemistry. 343: 335-7. PMID 15992759 DOI: 10.1016/J.Ab.2005.05.006  0.565
2005 Thomas PW, Stone EM, Costello AL, Tierney DL, Fast W. The quorum-quenching lactonase from Bacillus thuringiensis is a metalloprotein. Biochemistry. 44: 7559-69. PMID 15895999 DOI: 10.1021/Bi050050M  0.615
2005 Stone EM, Person MD, Costello NJ, Fast W. Characterization of a transient covalent adduct formed during dimethylarginine dimethylaminohydrolase catalysis. Biochemistry. 44: 7069-78. PMID 15865451 DOI: 10.1021/Bi047407R  0.673
Show low-probability matches.